stockrow
Friday 6 November 2026
Export GDTC’s income statement to Excel — free account
CytoMed Therapeutics Limited
GDTC Healthcare Biotechnology
CytoMed Therapeutics Limited’s revenue for fiscal 2025 (year ended December 2025) was $252,300.00, up 395.7% from fiscal 2024.
0.85
0.04
−4.49%
Follow GDTC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 0 | — | +395.7% | — | — | — | — | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | 0.00 | +100.0 pt | ||||||
| EBT | — | — | — | — | (1) | (1) | (2) | (3) | (2) | (3) | (4) | +17.2% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (3,626.52) | (1,231.79) | 0.00 | (1,231.8) pt | ||||||
| Net income | — | — | — | — | (1) | (2) | (2) | (3) | (2) | (3) | (8) | +17.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | 0.00 | 0.00 | (0.30) | (0.29) | (0.16) | (0.27) | (0.28) | n/m | ||||||
| Cash flow | — | — | — | — | 0.00 | 0.00 | (0.13) | (0.24) | (0.17) | (0.25) | 0.00 | +282.9% | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.04) | 0.00 | (0.09) | (0.05) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | 0.00 | 0.00 | (0.18) | (0.25) | (0.27) | (0.29) | 0.00 | +296.4% | ||||||
| Book value | — | — | — | — | 0.00 | 0.00 | 0.06 | 0.80 | 0.57 | 0.46 | 0.00 | +369.8% | ||||||
| Shares, m | — | — | — | — | 2,246 | 2,642 | 8 | 11 | 12 | 12 | — | (65.1%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 1,394.17 | 682.30 | 0.55 | 1,038.2 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (1,091.57) | (395.63) | (164.85) | (743.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (1) | (1) | (1) | (3) | (2) | (3) | (7) | +32.9% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | (1) | (1) | (2) | +23.3% | ||||||
| Free cash flow | — | — | — | — | (1) | (1) | (1) | (3) | (3) | (3) | (9) | +37.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (1) | 0 | (1) | 7 | 4 | 2 | 1,555 | n/m | |||||
| Net debt | — | — | — | — | 2 | 1 | 2 | (6) | (3) | (1) | (792) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | 0 | 2 | 0 | 9 | 7 | 5 | 4 | +71.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (41.27) | (55.54) | (47.20) | (22.00) | (45.59) | 0.00 | (45.6) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (48.09) | (42.67) | (20.94) | (27.51) | 0.00 | (27.5) pt | ||||||
| ROE | — | — | — | — | 0.00 | (133.76) | (197.96) | (69.92) | (24.33) | (51.81) | 0.00 | (51.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 28 | 34 | 43 | 42 | — | +14.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.01 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · fundamentals updated 2 Nov 2026
CytoMed Therapeutics Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PASG Passage Bio, Inc. | $11.1M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $10.7M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GDTC CytoMed Therapeutics Limited | $10.4M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | |
| BIVI BioVie Inc. | $10.3M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PTN Palatin Technologies, Inc. | $10.2M | 12.2× | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| INTS Intensity Therapeutics Inc. | $10.1M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AZR Azora Therapeutics, Inc. | $9.7M | — (loss-making) | — | — | n/m | −263.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GTBP GT Biopharma, Inc. | $9.4M | 0.8× | — | −100.00% (below 0%: shrinking) | n/m | −41.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PHIO Phio Pharmaceuticals Corp. | $9.3M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −58.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $10.1M | — | — | −56.18% | — | −18.31% | 0.00% | 0.00% |